Infectious diseases including chronic infections such as hepatitis B virus (HBV) remain leading causes of death worldwide. Influenza (Flu) and other respiratory infections kill ~half a million people globally each year, and our vaccines for many infections remain poorly effective, especially in vulnerable populations. Most fundamental insights into the mechanisms of immune responses to pathogens have come from animal models. Interrogating human immune system function has typically been limited to descriptive analyses or confirmation of observations from animal studies. This gap in knowledge limits our ability to use rational manipulation of specific immune pathways to effectively combat chronic infections and improve vaccines. The ongoing revolution in cancer immunotherapy ? in which blockade of immune checkpoints such as PD-1 is used to stimulate cancer immunity ? has not yet been exploited for human chronic infections and vaccines. Here we will test how PD-1 pathway blockade alters immunity in humans to chronic infections or vaccination, providing an opportunity to dissect the mechanistic role of this pathway in human innate and adaptive immunity. The studies proposed are highly innovative and have potential to reveal groundbreaking new fundamental knowledge of human immunity, because a) the PD-1 pathway is central to T and B cell responses to pathogens; and b) there is almost no information in humans about how blocking PD-1 affects cellular or humoral immunity to chronic viral infection or vaccines. Thus, the central goal of this Program is to employ specific immune perturbation through PD-1 blockade during persistent HBV infection and Flu vaccination, and use this intervention to define the innate and adaptive immune mechanisms controlled by PD-1 for improved therapeutic and preventative treatments for human infections. This Program will develop a broad platform with which to interrogate other existing or emerging immunotherapies and human immunity to infection. Thus, our U19 Program is organized around the following central hypothesis: ?We hypothesize that perturbing specific immunoregulatory pathways (e.g., PD-1) during human persisting viral infection and vaccination will provide insights into fundamental immune mechanisms involved in pathogen immunity and lead to novel opportunities for therapeutics and vaccines.? We will capitalize on this revolution in human immune system perturbation ? moved to the clinic initially for cancer ? to understand basic mechanisms of immune responses to persisting infections and vaccines. We propose 2 Projects to: 1) define how PD-1 blockade in humans re-invigorates HBV-specific CD8 T cell and bystander immune responses in HBV+ patients; and 2) test how PD-1 blockade impacts vaccine-induced CD4 T cell, B cell and antibody responses. The Projects are supported by administrative and scientific Cores to enable clinical sample acquisition, antibody evaluation and TCR, BCR and single-cell RNA sequencing.

Public Health Relevance

Program Narrative Infectious disease is a major cause of morbidity and mortality. The inability to perturb, and then study the effects of specific immune pathways in humans is a major limitation to developing better therapeutics against pathogens. Here we will exploit a novel immunotherapy (anti-PD-1) developed clinically for cancer, to investigate fundamental immune mechanisms in chronic HBV infection and during influenza vaccination.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
3U19AI082630-12S1
Application #
10149124
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Jiang, Chao
Project Start
2009-06-17
Project End
2022-05-31
Budget Start
2020-06-17
Budget End
2021-05-31
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156
Kurioka, Ayako; van Wilgenburg, Bonnie; Javan, Reza Rezaei et al. (2018) Diverse Streptococcus pneumoniae Strains Drive a Mucosal-Associated Invariant T-Cell Response Through Major Histocompatibility Complex class I-Related Molecule-Dependent and Cytokine-Driven Pathways. J Infect Dis 217:988-999
Qu, Chen; Zheng, Dandan; Li, Sai et al. (2018) Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology :
Yu, Wen-Han; Cosgrove, Cormac; Berger, Christoph T et al. (2018) ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection. Pathog Immun 3:2-18
Johnson, John L; Georgakilas, Georgios; Petrovic, Jelena et al. (2018) Lineage-Determining Transcription Factor TCF-1 Initiates the Epigenetic Identity of T Cells. Immunity 48:243-257.e10
Gordon, Claire L; Hutchings, Claire L; Highton, Andrew J et al. (2018) Memory inflation following adenoviral vaccination depends on IL-21. Vaccine 36:7011-7016
Carty, Shannon A; Gohil, Mercy; Banks, Lauren B et al. (2018) The Loss of TET2 Promotes CD8+ T Cell Memory Differentiation. J Immunol 200:82-91
Gordon, Claire Louse; Lee, Lian Ni; Swadling, Leo et al. (2018) Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8+ T Cells by Persistent Viruses and Vaccines. Cell Rep 23:768-782
Duan, Xiaoqiong; Li, Shilin; Holmes, Jacinta A et al. (2018) MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. J Virol 92:
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5

Showing the most recent 10 out of 173 publications